Read below, this is GERN!!!
Johnson and Johnson the most conservative pharmaceutical in the world loves GERN.
JNJ has 2 deals with GERN.
JNJ top cancer scientists will be presenting GERN'S drug by invitation to all of Europe June 15.
GERN drug is called transformational to medicine by Johnson and Johnson.
Johnson and Johnson brag that GERN'S drug is 1 of JNJ top future money makers.
The Mayo Clinic calls GERN'S drug tantamount to a cure and the only drug that returns bone marrow to normal.
Geron's President calls GERN'S drug bigger then all of us.
GERN'S drug has been shown to work on 90% of all 2,000 known cancers.
GERN'S drug technology won the Nobel Prize in medicine.
Just GERN'S cash is worth about $ 1 a share.
GERN also has deals with AST / BTX with royalties.
Geron also has deals with Sienna and GERN is the largest share holder of Sienna.
GERN has over 200 telomerase patents and Geron's President says you can't even say telomerase without going through Geron. GERN'S patents are good until 2033.
Geron’s blood cancer patients are living much longer then anyone thought possible.
GERN has over $1Billion in tax credits.
PCYC GERN'S is very similar to GERN only GERN'S technology is 1,000 better. PCYC was bought out by ABBVIE for $262 a share after Johnson and Johnson bid $220 a share. Maybe GERN will sell for $262 a share. Maybe GERN will sell for $100 a share but it is all good.
GERN gets $1 billion in milestone payments from 2 Johnson and Johnson deals.
GERN'S drugs works great in comb with other cancer drugs.
Listen to GERN'S President at the annual share holders meeting 46 minutes into to conference call. All very positive.
GERN'S second Johnson and Johnson deal here.
Johnson & Johnson’s ($JNJ) Janssen Pharmaceuticals has added to an existing partnership with the long-beleaguered Geron ($GERN). The new deal is for exclusive, worldwide rights to the biotech’s oligonucleotide backbone chemistry, as well as novel amidates for ribonucleic acid interference, or RNAi, to prevent, treat or diagnose any disease
The partnership specifically excludes approaches to blood or bone marrow originating cancers as well as any product that works primarily via telomerase inhibition; but these are already covered under an existing deal between the pair that dates back to November 2014.
In addition, Janssen gains a non-exclusive worldwide license to monomer synthesis technology; monomers are the building blocks of oligonucleotides and this is slated to be used as part of the imetelstat program already licensed under the 2014 deal. Imetelstat is a modified short oligonucleotide.
June 17 GERN update here.
The key issue here is that this forthcoming MDS presentation should include a meaty update regarding imetelstat's progress in the expanded subset of patients who are naive to lenalidomide and hypomethylating treatment and lack the del(5q) mutation. And as this is an oral presentation and not simply a poster, these data are probably going to be impressive. Oral conference presentations, after all, are typically reserved for substantial developments.
Now they are saying that telomerase is the key to aging and GERN owns all the telomerase patents too.
AI
